236 related articles for article (PubMed ID: 33152120)
61. Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study.
Mitani K; Lee JW; Jang JH; Tomiyama Y; Miyazaki K; Nagafuji K; Usuki K; Uoshima N; Fujisaki T; Kosugi H; Matsumura I; Sasaki K; Kizaki M; Sawa M; Hidaka M; Kobayashi N; Ichikawa S; Yonemura Y; Murotani K; Shimizu M; Matsuda A; Ozawa K; Nakao S
Blood Adv; 2024 Mar; 8(6):1415-1419. PubMed ID: 38134300
[No Abstract] [Full Text] [Related]
62. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
63. Romiplostim: a novel thrombopoiesis-stimulating agent.
Perreault S; Burzynski J
Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
[TBL] [Abstract][Full Text] [Related]
64. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D
Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874
[TBL] [Abstract][Full Text] [Related]
65. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.
Hartranft ME; Clemmons AB; DeRemer DL; Kota V
J Oncol Pharm Pract; 2017 Jan; 23(1):10-17. PubMed ID: 26471738
[TBL] [Abstract][Full Text] [Related]
67. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
68. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
69. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
70. Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial.
Kurita N; Nishikii H; Maruyama Y; Suehara Y; Hattori K; Sakamoto T; Kato T; Yokoyama Y; Obara N; Maruo K; Ohigashi T; Yamaguchi H; Iwamoto T; Minohara H; Matsuoka R; Hashimoto K; Sakata-Yanagimoto M; Chiba S
Ann Hematol; 2023 Oct; 102(10):2895-2902. PubMed ID: 37589942
[TBL] [Abstract][Full Text] [Related]
71. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
[TBL] [Abstract][Full Text] [Related]
72. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
Shinohara K; Kambara N
Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
[TBL] [Abstract][Full Text] [Related]
73. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
74. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Le Rhun E; Devos P; Houillier C; Cartalat S; Chinot O; Di Stefano AL; Lepage C; Reyns N; Dubois F; Weller M
Neurology; 2019 Nov; 93(19):e1799-e1806. PubMed ID: 31586022
[TBL] [Abstract][Full Text] [Related]
75. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
76. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
[TBL] [Abstract][Full Text] [Related]
77. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.
Janssens A; Tarantino M; Bird RJ; Mazzucconi MG; Boccia RV; Fernández MF; Kozak T; Steurer M; Boekhorst Pt; Dillingham K; Kreuzbauer G; Woodard P
Acta Haematol; 2015; 134(4):215-28. PubMed ID: 26066765
[TBL] [Abstract][Full Text] [Related]
78. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
[TBL] [Abstract][Full Text] [Related]
79. Erythematous rash following romiplostim administration in a patient with autoimmune lymphoproliferative syndrome.
Biondo L; Bodge M; Paul SR
Ann Pharmacother; 2013 Jan; 47(1):e7. PubMed ID: 23300150
[TBL] [Abstract][Full Text] [Related]
80. Romiplostim resistance in secondary failure of platelet recovery.
DeRemer DL; Katsanevas K; Bradley A; Awan FT
J Oncol Pharm Pract; 2013 Dec; 19(4):369-72. PubMed ID: 23292974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
